<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01348256</url>
  </required_header>
  <id_info>
    <org_study_id>CD-2009-01</org_study_id>
    <secondary_id>2008-007795-23</secondary_id>
    <nct_id>NCT01348256</nct_id>
  </id_info>
  <brief_title>Study With Dendritic Cell Immunotherapy in Resected Hepatic Metastasis of Colorectal Carcinoma</brief_title>
  <official_title>Randomized Phase II Study With Dendritic Cell Immunotherapy in Patients With Resected Hepatic Metastasis of Colorectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this randomized multicentric phase II study, patients with colorectal carcinoma with
      resectable hepatic metastasis will be randomized to treatment with dendritic cells or to
      observation, following conventional treatment with surgery and chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free survival</measure>
    <time_frame>Progression free survival at 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Colorectal Carcinoma</condition>
  <condition>Hepatic Metastasis</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observation after standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dendritic cells vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvant treatment with dendritic cells vaccine after standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dendritic cells vaccine</intervention_name>
    <description>Vaccination with autologous dendritic cells loaded with autologous tumor antigens</description>
    <arm_group_label>Dendritic cells vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age over 18 years.

          2. Confirmed diagnosis of colorectal cancer with hepatic metastasis, amenable for
             surgical treatment.

          3. Capacity of understanding and signing the informed consent and to undergo the study
             procedures

          4. Availability of tumor tissue, for maturing dendritic cells

          5. Adequate renal, hepatic and bone marrow function

        Exclusion Criteria:

          1. Clinically relevant diseases or infections.

          2. Concurrent participation in other clinical trial or administration or other
             antitumoral treatment

          3. Concurrent cancer, with the exceptions allowed by the principal investigator (PI).

          4. Pregnant or breast feeding women

          5. Immunosuppressant treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ignacio Melero, MDPhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Navarra</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ignacio Melero, MD, PHD</last_name>
    <phone>+34 948 255 400</phone>
    <email>imelero@unav.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ignacio Melero, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ruth Vera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2011</study_first_submitted>
  <study_first_submitted_qc>May 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2011</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal carcinoma</keyword>
  <keyword>resectable hepatic metastasis</keyword>
  <keyword>adjuvant treatment</keyword>
  <keyword>dendritic cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

